183 related articles for article (PubMed ID: 23485022)
41. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
42. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
43. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
[TBL] [Abstract][Full Text] [Related]
44. Alcohol exposure alters pre-mRNA splicing of antiapoptotic Mcl-1L isoform and induces apoptosis in neural progenitors and immature neurons.
Donadoni M; Cicalese S; Sarkar DK; Chang SL; Sariyer IK
Cell Death Dis; 2019 Jun; 10(6):447. PubMed ID: 31171771
[TBL] [Abstract][Full Text] [Related]
45. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
46. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
47. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
48. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
49. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
50. Mcl-1 and Bcl-x
Hockings C; Alsop AE; Fennell SC; Lee EF; Fairlie WD; Dewson G; Kluck RM
Cell Death Differ; 2018 Mar; 25(4):721-734. PubMed ID: 29459767
[TBL] [Abstract][Full Text] [Related]
51. [The effect of cell killing by ABT-737 synergized with docetaxel in human prostate cancer PC-3 cells].
Hao JW; Mao XP; Ding DG; Du GH; Liu ZH
Zhonghua Wai Ke Za Zhi; 2012 Feb; 50(2):161-5. PubMed ID: 22490358
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
Harnett CC; Abusneina A; Clément J; Gauthier ER
Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811
[TBL] [Abstract][Full Text] [Related]
53. Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis.
Yamaguchi R; Perkins G
Cell Death Dis; 2011 Nov; 2(11):e227. PubMed ID: 22071632
[No Abstract] [Full Text] [Related]
54. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
[TBL] [Abstract][Full Text] [Related]
55. Chemical Inhibition of Pre-mRNA Splicing in Living Saccharomyces cerevisiae.
Hansen SR; Nikolai BJ; Spreacker PJ; Carrocci TJ; Hoskins AA
Cell Chem Biol; 2019 Mar; 26(3):443-448.e3. PubMed ID: 30639260
[TBL] [Abstract][Full Text] [Related]
56. Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines.
Xu H; Krystal GW
Clin Cancer Res; 2010 Sep; 16(17):4392-400. PubMed ID: 20732961
[TBL] [Abstract][Full Text] [Related]
57. Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators.
Aird D; Teng T; Huang CL; Pazolli E; Banka D; Cheung-Ong K; Eifert C; Furman C; Wu ZJ; Seiler M; Buonamici S; Fekkes P; Karr C; Palacino J; Park E; Smith PG; Yu L; Mizui Y; Warmuth M; Chicas A; Corson L; Zhu P
Nat Commun; 2019 Jan; 10(1):137. PubMed ID: 30635584
[TBL] [Abstract][Full Text] [Related]
58. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
59. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.
Song L; Coppola D; Livingston S; Cress D; Haura EB
Cancer Biol Ther; 2005 Mar; 4(3):267-76. PubMed ID: 15753661
[TBL] [Abstract][Full Text] [Related]
60. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
